Why CUE-221 Might Not Beat Omalizumab In CSU And Could Still Separate In Food Allergy

Disclosure: The author holds a beneficial long position in Cue Biopharma (NASDAQ: CUE) and no position in any other company mentioned. This article is for informational and educational purposes only and is not financial advice. Although the author is a physician, this content is commentary on the underlying science and does not constitute medical advice, diagnosis, or treatment recommendation. The author receives no compensation for this article and has no business relationship with the companies mentioned. See the full Legal Information and Disclosures section below.

In May I cautiously argued that licensing the "dual-mechanism" anti-IgE antibody CUE-221 might be a major opportunity for Cue Biopharma, a small clinical-stage Boston-based biotech. United BioPharma in Taiwan developed it as UB-221, and Ascendant Health Sciences, which renamed it Ascendant-221, licensed it to Cue for everything outside greater China in April 2026. The Phase 2 in chronic spontaneous urticaria (CSU) is running in China under a company related to Ascendant, and Cue expects the readout by the end of the third quarter, after which it plans to start its own Phase 2b in food allergy once it has reviewed the data.

Both CSU and food allergy depend on IgE bound to FcεRI on mast cells and basophils. In food allergy the IgE is allergen-specific, and cross-linking by the allergen triggers degranulation and the immediate allergic reaction. The same degranulation happens in CSU without an external allergen, since in the more common of two autoimmune mechanisms the cross-linking IgE is autoreactive and binds self-antigens such as thyroid peroxidase and IL-24, while a smaller group of patients instead carries IgG autoantibodies against IgE or its receptor.

IgE also engages a second receptor, CD23 (FcεRII), through which its own production is regulated. Omalizumab binds the Cε3 domain across a surface that substantially overlaps the site IgE uses to contact CD23, and blocks that interaction sterically. Ligelizumab overlaps that site only marginally, and inhibits IgE binding to CD23 less potently, working through competition for surface residues and through stabilizing an open Cε3 conformation rather than through the substantial steric conflict omalizumab creates. Kuo et al. reported that 8D6, the murine precursor of CUE-221, binds Cε2 and Cε3 through a mixed protein-carbohydrate epitope at a distance from the CD23 site, and attributed the same binding mode to CUE-221, which would leave IgE able to reach CD23 while CUE-221 still neutralizes it.

Kuo et al. reported that on a CD23-immobilized ELISA, free CUE-221 bound CD23-occupied IgE with an EC50 of about 38 ng/mL against roughly 402 ng/mL for ligelizumab, and CUE-221 already complexed with IgE bound at about 42 ng/mL, so neither form was excluded from binding in that assay. In cultures of peripheral blood mononuclear cells stimulated with IL-4 and anti-CD40 to drive fresh IgE production, CUE-221 suppressed new IgE protein by up to 69 to 74 percent at 10 μg/mL and above, against 16 to 31 percent for ligelizumab and 5 to 31 percent for omalizumab.

Every UB-221 laboratory and preclinical result cited here comes from a single paper, Kuo et al. in the Journal of Clinical Investigation in 2022, sponsored by United BioPharma, which developed and owned the antibody, and written by salaried employees of its corporate group together with the academic dermatologists who ran the Phase 1, so no independent characterization of CUE-221 appears to have been published (which is not unusual for a proprietary molecule).

Kuo et al. also described ligelizumab's reduction in IgE synthesis as of minor significance, and suggested that omalizumab and ligelizumab may operate in the clinic mainly as IgE neutralizers. Omalizumab may nevertheless have a route of its own to lower IgE production, as it reduced germline Cε and IL-4Rα transcripts in about half of tonsillar B-cell samples in vitro. CD23 signaling also runs in both directions, since soluble CD23 upregulates IgE synthesis while the membrane form contributes to negative feedback, so blocking the IgE-CD23 interaction may remove an accelerator as well as a brake. Whether any of these differences change IgE production in treated patients has not been tested for CUE-221.

Cue describes the study as a placebo and active comparator-controlled dose-ranging Phase 2 in CSU in China, and its entry on the Center for Drug Evaluation's national drug clinical trial registry, published in Chinese and read through Google Chrome's translation on 26 August 2026 under registration number CTR20233674 and protocol number UBP-A237-IgE, sets the doses and the endpoint schedule out in full and records recruitment as complete at 145 patients against a registered target of 144. Ascendant-221 is administered subcutaneously at 1, 2 and 4 mg/kg over five four-week cycles, against omalizumab 300 mg on the same cycle and against placebo. The primary endpoint is the proportion of patients reaching a weekly hives severity score of zero at week 12, which the registry frames as a comparison against placebo rather than against the omalizumab arm, and serum free and total IgE sit among the secondary endpoints, assessed at week 37 on the registry's schedule.

To my knowledge ligelizumab is the only anti-IgE with an epitope of its own to have been taken through Phase 3 against omalizumab in CSU. It binds IgE more tightly and, in atopic volunteers, was reported to suppress free IgE and basophil surface IgE further and for longer. Its 382-patient Phase 2b ran on the same endpoint the Ascendant-221 trial has registered, a weekly hives severity score of zero at week 12, and reached 51 percent complete hives response on 72 mg against 26 percent on omalizumab 300 mg and 0 percent on placebo. Novartis then randomized 2057 adults across PEARL-1 and PEARL-2, where ligelizumab proved superior to placebo and not to omalizumab, with week 12 UAS7 change indistinguishable and complete response at week 24, scored as a UAS7 of zero rather than on the hives component alone, slightly higher on omalizumab at 43.4 percent than on either ligelizumab dose, at 38.7 and 42.9 percent.

In ASTERIA II, one of omalizumab's registration trials, a post hoc analysis found 53 percent of patients on omalizumab 300 mg free of hives at week 12, against the 26 percent at the same timepoint in the ligelizumab Phase 2b, which scores the same hives component of the urticaria activity score under a different name. Maurer and colleagues noted that their omalizumab arm fell below earlier studies and pointed to differences in their enrolled population, among them a higher share carrying the type IIb autoimmune component. The Ascendant-221 trial's registry entry requires only that patients be refractory to antihistamines and specifies no dose, which leaves open a population closer to ASTERIA II's. When a control arm underperforms, a new drug appears artificially superior, and if omalizumab performs at its historical baseline here, Ascendant-221 would have much less room to separate.

The Phase 2 of Ascendant-221 in CSU enrolled fewer patients than the ligelizumab Phase 2b that produced a result Phase 3 could not confirm. A complete-response rate is a proportion, and in a trial this size it carries enough sampling error that a difference against omalizumab in either direction would be weak evidence and easily consistent with noise.

Free and total IgE are what I would watch, and not as a consolation if the symptom scores in CSU disappoint. Both are registered as secondary endpoints out to week 37, though a topline release may not report them. They are continuous measurements rather than proportions, and they report on IgE directly instead of through a symptom score. If the CD23 mechanism translates from culture into patients, it might show as total IgE rising less than it does on omalizumab, or as free IgE staying suppressed while serum drug concentrations fall.

Total IgE may be the more informative of the two measurements, since omalizumab raises it as drug-IgE complexes accumulate and clear far more slowly than free IgE. Kuo et al. reported that CUE-221 also forms mAb-IgE complexes, with the predominant species running from a 3:3 heterohexamer at equimolar ratios to a 1:1 heterodimer once the antibody is in tenfold excess, so its total IgE may reflect the balance between any such accumulation and any reduction in synthesis. The animal and Phase 1 data measured free IgE rather than total. It fell by 90 percent or more in macaques and IgE-knockin mice, and it was the only IgE measure reported in the Phase 1 in CSU patients, so no total-IgE readout for this antibody in humans appears to have been published.

The Phase 2 also runs at lower single doses and by a different route, 1 to 4 mg/kg subcutaneously against intravenous doses of up to 10 mg/kg in the Phase 1, where Cue reported free IgE held down beyond twelve weeks and Kuo et al. reported full suppression in the 6 and 10 mg/kg cohorts of three patients each, fifteen participants across the five dose levels in all, with the reduction in symptom scores persisting longer at those doses over fourteen weeks of monitoring. Dosing every four weeks for five cycles may nevertheless build to an exposure the single-dose Phase 1 never reached, so the comparison does not run cleanly in one direction, and at that cohort size the pharmacodynamic separation may still be smaller than a single high intravenous dose would suggest.

Food allergy trials usually measure outcomes against a fixed threshold rather than a symptom score. In the Phase 3 OUtMATCH trial, which enrolled patients reacting to 100 mg of peanut protein or less and to 300 mg or less of two other study foods, 79 of 118 children and adolescents on omalizumab tolerated a single 600 mg dose without dose-limiting symptoms, against 4 of 59 on placebo. The trial met its primary endpoint comfortably, and 39 treated patients did not reach the 600 mg threshold, some of whom may have improved without crossing it. Reviewing the label population for the February 2024 approval, the FDA recorded that 17 percent had no significant change in the amount of peanut protein tolerated, still reacting at 100 mg or less after treatment. Those patients are where a further reduction in IgE might improve response and allergen tolerability.

Ligelizumab went into Phase 3 in peanut allergy against the same 600 mg threshold and the same entry criterion, where 44.7 percent tolerated 600 mg on 240 mg every four weeks against 4.3 percent on placebo, and 15.7 percent on 120 mg. Novartis stopped the study early after a blinded review indicated the target would not be met, and pointed to the dosing regimen rather than to the molecule. The internal dose response fits that reading, since doubling the dose nearly tripled the responder rate in a study that dosed flat irrespective of weight or IgE burden, while OUtMATCH set each omalizumab dose from weight and baseline total IgE and reached 67 percent in a younger population. How far free IgE falls may be a stoichiometric problem as much as an affinity one, since the antibody has to be present in molar excess over the patient's IgE burden, and a tighter binding constant does little to change that once both antibodies are already titrating in the sub-nanomolar range.

GSK paid roughly 2.2 billion dollars for RAPT Therapeutics in early 2026, principally for ozureprubart, a bio-better on omalizumab's epitope carrying the three YTE mutations and a half-life long enough for its Phase 2b to test eight- and twelve-week dosing in food allergy. The same abstract puts its inhibition of IgE binding to FcεRI two- to threefold above omalizumab's. The shared epitope keeps it outside the CD23 route, and the patients omalizumab leaves below the threshold may stay below it on ozureprubart.

Cue announced on August 3 that it had recently submitted the food allergy IND, and plans to begin the global Phase 2b once the data from the Phase 2 in CSU have been reviewed. With 145 patients spread across five groups and a primary endpoint registered against placebo, the trial may not settle the comparison with omalizumab in either direction. The IgE levels are the part I will be reading, and if total IgE on Ascendant-221 rises to the same multiple as on omalizumab and free IgE returns to baseline on the same timeline after dosing ends, the CD23 mechanism has not shown up in patients.

Follow me on X for frequent updates (@chaotropy).

Legal Information and Disclosures

General Disclaimer & No Financial Advice: The author is not a registered investment advisor or financial analyst, and nothing here is financial, legal, tax, or investment advice, a personal recommendation, an assessment of suitability for any investor, or an offer, solicitation, or recommendation regarding any security. This is not a securities research report and was not prepared under the requirements designed to promote the independence of investment research. It has not been peer-reviewed or audited, represents the author's opinion as of the publication date, and may change without notice. Readers should conduct their own due diligence and consult a certified financial professional before making any investment decision. Readers act on this content at their own risk, and to the fullest extent permitted by applicable law the author accepts no liability for any loss or damage arising from reliance on it.

Medical Disclaimer: The author is a physician, but this article discusses clinical trials and drug mechanisms as general scientific and educational commentary. It is not medical advice, diagnosis, or a treatment recommendation, and it establishes no physician-patient relationship. Readers should never disregard or delay professional medical advice because of anything written here, and should consult a qualified healthcare provider about any medical condition.

Accuracy and Third-Party Data: Data here come from national clinical trial registries, SEC filings, company communications, peer-reviewed journals, conference abstracts, news reports, and government publications, believed reliable but not guaranteed complete, current, or correct. Some figures cited are drawn from post hoc analyses rather than prespecified endpoints, and results for competitor programs may derive from company announcements or from conference abstracts authored by the sponsor rather than from peer-reviewed publication or a registry results posting, have not been independently verified, and may change when full datasets appear. The doses and the endpoint schedule of the Phase 2 study of CUE-221 in chronic spontaneous urticaria are taken from its entry in the national drug clinical trial registry maintained by China's Center for Drug Evaluation. That entry is published in Chinese and was read in machine translation, so wording-level details, including the framing of the primary endpoint, may not be exact. It is more detailed than Cue Biopharma's own account of the study and is not mirrored on ClinicalTrials.gov. The registry does not issue stable per-trial links, so the entry is cited here by registration number and access date rather than by permalink. Despite the author's efforts to verify the sources cited, this article may contain errors of fact or interpretation.

Disclosure of Interest: The author holds a beneficial long position in Cue Biopharma, Inc. (NASDAQ: CUE), and holds no position, long or short, in any other company mentioned. The author reserves the right to buy or sell securities of Cue Biopharma at any time without further notice. He received no compensation for this article, maintains no business relationship with any company mentioned, and has no access to non-public trial data, unblinded interim results, or internal company information. His position in Cue creates a potential for confirmation bias in interpreting the underlying science, which systematic analysis and conservative assumptions may reduce but not remove.

Forward-Looking Statements & Risk: Statements here about regulatory outcomes, clinical results, and market potential are predictions based on current expectations, subject to significant risks and uncertainties, and actual results may differ materially. The Phase 2 study of CUE-221 in chronic spontaneous urticaria remains ongoing as of publication, the author has no access to unblinded data, and the results could differ substantially from any inference drawn here. The food allergy IND has been submitted but not cleared, and the global Phase 2b has not been initiated, leaving its design, endpoints, dose, and timing subject to change. Every comparison drawn between CUE-221, omalizumab, ligelizumab and ozureprubart is cross-trial and non-randomized, involves different populations, timepoints, and scoring instruments, and no head-to-head clinical data in food allergy exist. The in vitro and ex vivo findings cited for CUE-221 are single-laboratory results whose translation to patients is unproven. Biotechnology and pharmaceutical investing carries a high degree of risk, including total loss of principal. Cue Biopharma has repeatedly disclosed substantial doubt about its ability to continue as a going concern, including in its quarterly report for the period ended 31 March 2026. Readers should consult its most recent SEC filings for the current position and capital requirements. Past performance does not indicate future results.

Copyright: Original text and images are the property of the author and may not be copied, reproduced, or published in whole or in part without prior written consent, except as applicable law or the publishing platform permits. Use of this content to train machine learning or AI models requires explicit authorization. Third-party and public domain images remain subject to their respective rights and are not claimed as the author's property.